Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;2(1):100065.
doi: 10.1016/j.jcvp.2022.100065. Epub 2022 Jan 15.

Fast and reliable real life data on COVID-19 triaging with ID NOW

Elisa Burdino  1 , Francesco Cerutti  1 , Maria Grazia Milia  1 , Tiziano Allice  1 , Gabriella Gregori  1 , Franco Aprà  2 , Fabio De Iaco  2 , Enzo Aluffi  3 , Gianmatteo Micca  3 , Valeria Ghisetti  1
Affiliations

Fast and reliable real life data on COVID-19 triaging with ID NOW

Elisa Burdino et al. J Clin Virol Plus. 2022 Feb.

Abstract

In the context of SARS-CoV-2 pandemic, rapid and easy-to-perform diagnostic methods are essential to limit the spread of the virus and for the clinical management of COVID-19 patients. Although real-time polymerase chain reaction remains the "gold standard" to diagnose acute infections, this technique is expensive, requires trained personnel, well-equipped laboratory and is time-consuming. A prospective evaluation of the Abbott ID NOW COVID-19 point-of-care testing that uses isothermal nucleic acid amplification for the qualitative detection of SARS-CoV-2 RdRp gene was run in the Emergency Department during the third wave of COVID-19 pandemic. ID-NOW significantly simplified SARS-CoV-2 identification and COVID-19 patient triaging, being highly valuable in rapidly locating febrile patients in or out of COVID-19 areas, and can be considered as a first-line diagnostic test in the Emergency Room setting.

Keywords: Abbott ID NOW; COVID-19; Point-of-care; Rapid molecular testing; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Dinnes J., Deeks J.J., Berhane S., Taylor M., Adriano A., Davenport C., Dittrich S., Emperador D., Takwoingi Y., Cunningham J., Beese S., Domen J., Dretzke J., Ferrante di Ruffano L., Harris I.M., Price M.J., Taylor-Phillips S., Hooft L., Leeflang M.M.G., McInnes M.D.F., Spijker R., Van den Bruel A., Arevalo-Rodriguez I., Buitrago D.C., Ciapponi A., Mateos M., Stuyf T., Horn S., Salameh J.P., McGrath T.A., van der Pol C.B., Frank R.A., Prager R., Hare S.S., Dennie C., Jenniskens K., Korevaar D.A., Cohen J.F., van de Wijgert J., Damen J.A.A.G., Wang J., Agarwal R., Baldwin S., Herd C., Kristunas C., Quinn L., Scholefield B. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2021:2021. doi: 10.1002/14651858.CD013705.pub2. - DOI - PMC - PubMed
    1. FDA website: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em... (last access: 17/01/2022)
    1. Tu Y.P., Iqbal J., O'leary T. Sensitivity of ID NOW and RT–PCR for detection of SARS-CoV-2 in an ambulatory population. Elife. 2021:10. doi: 10.7554/ELIFE.65726. - DOI - PMC - PubMed
    1. Craney A.R., Velu P.D., Satlin M.J., Fauntleroy K.A., Callan K., Robertson A., la Spina M., Lei B., Chen A., Alston T., Rozman A., Loda M., Rennert H., Cushing M., Westblade L.F. Comparison of two high-throughput reverse transcription-PCR systems for the detection of severe acute respiratory syndrome coronavirus 2. J. Clin. Microbiol. 2020;58:1–6. doi: 10.1128/JCM.00890-20. - DOI - PMC - PubMed
    1. Lieberman J.A., Pepper G., Naccache S.N., Huang M.L., Jerome K.R., Greninger A.L. Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J. Clin. Microbiol. 2020;58:1–6. doi: 10.1101/2020.04.24.20074559. - DOI - PMC - PubMed